Please select the eligibility criteria that correspond to the clinical trial below.
Title: Laparoscopic Sleeve Gastrectomy or Laparoscopic Proximal Roux-Y-gastric Bypass in the Treatment of Morbid Obesity
Brief Summary: The laparoscopic sleeve-gastrectomy (SG) compared to laparoscopic proximal Roux-Y-gastric bypass (PGB) is as successful in the treatment of morbid obesity in the majority of patients. In case of insufficient weight loss malabsorption can to be added by performing laparoscopic bilious-pancreatic diversion duodenal switch (BPD). The resection of the gastric fundus (LG) leads to changes in gastrointestinal hormones that are possibly different to bypassing the fundus (PGB).


Options:
A: Inclusion Criteria:

* Type 2 diabetes mellitus with HbA1c \> 7.0%
* Body mass index \> 27 and \< 43 kg/m2
* Candidate for general anesthesia

Exclusion Criteria:

* Prior bariatric surgery of any kind
* Cardiovascular conditions including significant coronary artery disease, peripheral vascular disease, uncompensated congestive heart failure, history of stroke, or uncontrolled hypertension
* Kidney disease or chronic renal insufficiency with a creatinine level \> 1.8 mg/dl
* Known history of chronic liver disease (except for NAFLD/NASH)
* Gastrointestinal disorders, malabsorptive disorders, or inflammatory bowel disease
* Psychiatric disorders including dementia, active psychosis, severe depression requiring \> 2 medications, history of suicide attempts, alcohol or drug abuse within the previous 12 months
* Severe pulmonary disease defined as FEV1 \< 50% of predicted value
* Pregnancy
B: Swiss patients with approval by health insurance

Patients from outside Switzerland: only if patients or their insurance will cover the costs

Inclusion Criteria:

* BMI\>40

Exclusion Criteria:

* contraindication for bariatric surgery
C: Inclusion Criteria:

* Morbidly obese patients

Exclusion Criteria:

-
D: Inclusion Criteria:

* Age \> 18 years and \< 55 years - Male or Female
* BMI \> 35 with significant comorbidities (i.e. hypertension, or hyperlipidemia, or diabetes) or \> 40 BMI \<60 (with or without a co-morbid condition)
* History of failure with nonsurgical weight loss methods
* Candidates for Roux-en-Y gastric bypass
* Patients willing to comply with study requirements
* Patients who have signed an informed consent form

Exclusion Criteria:

* Patients requiring prescription anticoagulation therapy
* Patients with iron deficiency and iron deficiency anemia
* Inflammatory bowel disease or condition of the gastrointestinal tract, such as ulcers or Crohn's disease
* Treatment represents an unreasonable risk to the patient
* Pancreatitis or other serious organic conditions
* Symptomatic coronary artery disease or pulmonary dysfunction
* Patients with known gallstones prior to implant
* Known infection at the time of implant
* Severe coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia
* Congenital or acquired anomalies of the GI tract such as atresias or stenoses
* Pregnant or has the intention of becoming pregnant in the next 12 months
* Unresolved alcohol or drug addiction
* HIV Positive patients
* Patients with hepatitis B or C
* Mentally retarded or emotionally unstable, or exhibits psychological characteristics which, in the opinion of the investigator, makes the subject a poor candidate for device placement or clinical trial
* Previous GI surgery that could affect the ability to place the sleeve or the function of the implant.
* Patients unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period
* H. pylori positive patients (Note: patients may be enrolled if they had a prior history and were successfully treated)
* Patients receiving weight loss medications such as Meridia and Xenical
* Family or patient history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder
* Patients with gastroesophageal reflux disease (GERD)
* Patients with a history of kidney stones
* Participating in another ongoing investigational clinical trial

Answer: B